Anticardiolipin antibodies in patients with liver disease

A. Mangia, M. Margaglione, I. Cascavilla, R. Gentile, G. Cappucci, D. Facciorusso, E. Grandone, G. Di Minno, M. Rizzetto, A. Andriulli

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Our aim was to test the hypothesis that anticardiolipin antibodies (aCL) may cause an antiphospholipid syndrome and thrombotic events in patients with liver disease. METHODS: aCL were measured in 116 healthy controls and 372 patients with liver disease of different stage and etiology: 136 cases secondary to hepatitis C virus (HCV) infection, 139 due to hepatitis B virus (HBV) infection, 69 with alcoholic liver damage, and 28 cryptogenic in origin. Prior thrombotic events were recorded. The results were related to age, gender, stage, severity, and etiology of the liver disease, as well as to the occurrence of organ- and nonorgan-specific autoantibodies. RESULTS: aCL were positive in 4.4% of controls and in 18.8% of patients (p <0.0002). Patients with aCL were more frequently men with an advanced cirrhosis and simultaneous occurrence of anti-smooth-muscle antibodies (ASMA) in serum (p <0.0006); their liver damage was often secondary to HBV (37.3%) or alcohol abuse (18.5%). At conditional logistic regression analysis, only the presence of ASMA (odds ratio [OR] = 3.02, 95% confidence interval [CI] 1.7-5.5, p = 0.0003), HBV (OR = 3.4, 95% CI 1.6-7.2, p = 0.0013), or alcoholic liver disease (OR = 5.3, 95% CI 2.3-12.2, p = 0.0001) were independently associated with aCL. Thrombosis was encountered in 24 patients (6.4%). At conditional logistic regression analysis, thrombosis was significantly associated with advanced age (OR = 1.07, 95% CI 1.0-1.1, p = 0.0094), development of hepatocellular carcinoma (OR = 17.8, 95% CI 1.6- 196.0, p = 0.01), HBV etiology (OR = 6.3, 95% CI, 1.6-24.6, p = 0.0076), or cryptogenic liver disease (OR = 54.8, 95% CI 5-599.9, p = 0.001). Of the five patients with newly documented portal thrombosis during the follow-up, only one tested positive for aCL. CONCLUSIONS: In patients with nonautoimmune liver disease, aCL production is an epiphenomenon of the liver damage and is not associated with thrombotic complications. These data do not support the hypothesis that HCV is a cause of the antiphospholipid syndrome.

Original languageEnglish
Pages (from-to)2983-2987
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume94
Issue number10
DOIs
Publication statusPublished - Oct 1999

Fingerprint

Anticardiolipin Antibodies
Liver Diseases
Odds Ratio
Confidence Intervals
Hepatitis B virus
Thrombosis
Antiphospholipid Syndrome
Virus Diseases
Hepacivirus
Smooth Muscle
Liver
Logistic Models
Regression Analysis
Alcoholic Liver Diseases
Antibodies
Autoantibodies
Alcoholism
Antibody Formation
Hepatocellular Carcinoma
Fibrosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Anticardiolipin antibodies in patients with liver disease. / Mangia, A.; Margaglione, M.; Cascavilla, I.; Gentile, R.; Cappucci, G.; Facciorusso, D.; Grandone, E.; Di Minno, G.; Rizzetto, M.; Andriulli, A.

In: American Journal of Gastroenterology, Vol. 94, No. 10, 10.1999, p. 2983-2987.

Research output: Contribution to journalArticle

Mangia, A, Margaglione, M, Cascavilla, I, Gentile, R, Cappucci, G, Facciorusso, D, Grandone, E, Di Minno, G, Rizzetto, M & Andriulli, A 1999, 'Anticardiolipin antibodies in patients with liver disease', American Journal of Gastroenterology, vol. 94, no. 10, pp. 2983-2987. https://doi.org/10.1111/j.1572-0241.1999.01447.x
Mangia A, Margaglione M, Cascavilla I, Gentile R, Cappucci G, Facciorusso D et al. Anticardiolipin antibodies in patients with liver disease. American Journal of Gastroenterology. 1999 Oct;94(10):2983-2987. https://doi.org/10.1111/j.1572-0241.1999.01447.x
Mangia, A. ; Margaglione, M. ; Cascavilla, I. ; Gentile, R. ; Cappucci, G. ; Facciorusso, D. ; Grandone, E. ; Di Minno, G. ; Rizzetto, M. ; Andriulli, A. / Anticardiolipin antibodies in patients with liver disease. In: American Journal of Gastroenterology. 1999 ; Vol. 94, No. 10. pp. 2983-2987.
@article{fb0b23545b85467097e4aacd2096458c,
title = "Anticardiolipin antibodies in patients with liver disease",
abstract = "OBJECTIVE: Our aim was to test the hypothesis that anticardiolipin antibodies (aCL) may cause an antiphospholipid syndrome and thrombotic events in patients with liver disease. METHODS: aCL were measured in 116 healthy controls and 372 patients with liver disease of different stage and etiology: 136 cases secondary to hepatitis C virus (HCV) infection, 139 due to hepatitis B virus (HBV) infection, 69 with alcoholic liver damage, and 28 cryptogenic in origin. Prior thrombotic events were recorded. The results were related to age, gender, stage, severity, and etiology of the liver disease, as well as to the occurrence of organ- and nonorgan-specific autoantibodies. RESULTS: aCL were positive in 4.4{\%} of controls and in 18.8{\%} of patients (p <0.0002). Patients with aCL were more frequently men with an advanced cirrhosis and simultaneous occurrence of anti-smooth-muscle antibodies (ASMA) in serum (p <0.0006); their liver damage was often secondary to HBV (37.3{\%}) or alcohol abuse (18.5{\%}). At conditional logistic regression analysis, only the presence of ASMA (odds ratio [OR] = 3.02, 95{\%} confidence interval [CI] 1.7-5.5, p = 0.0003), HBV (OR = 3.4, 95{\%} CI 1.6-7.2, p = 0.0013), or alcoholic liver disease (OR = 5.3, 95{\%} CI 2.3-12.2, p = 0.0001) were independently associated with aCL. Thrombosis was encountered in 24 patients (6.4{\%}). At conditional logistic regression analysis, thrombosis was significantly associated with advanced age (OR = 1.07, 95{\%} CI 1.0-1.1, p = 0.0094), development of hepatocellular carcinoma (OR = 17.8, 95{\%} CI 1.6- 196.0, p = 0.01), HBV etiology (OR = 6.3, 95{\%} CI, 1.6-24.6, p = 0.0076), or cryptogenic liver disease (OR = 54.8, 95{\%} CI 5-599.9, p = 0.001). Of the five patients with newly documented portal thrombosis during the follow-up, only one tested positive for aCL. CONCLUSIONS: In patients with nonautoimmune liver disease, aCL production is an epiphenomenon of the liver damage and is not associated with thrombotic complications. These data do not support the hypothesis that HCV is a cause of the antiphospholipid syndrome.",
author = "A. Mangia and M. Margaglione and I. Cascavilla and R. Gentile and G. Cappucci and D. Facciorusso and E. Grandone and {Di Minno}, G. and M. Rizzetto and A. Andriulli",
year = "1999",
month = "10",
doi = "10.1111/j.1572-0241.1999.01447.x",
language = "English",
volume = "94",
pages = "2983--2987",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Anticardiolipin antibodies in patients with liver disease

AU - Mangia, A.

AU - Margaglione, M.

AU - Cascavilla, I.

AU - Gentile, R.

AU - Cappucci, G.

AU - Facciorusso, D.

AU - Grandone, E.

AU - Di Minno, G.

AU - Rizzetto, M.

AU - Andriulli, A.

PY - 1999/10

Y1 - 1999/10

N2 - OBJECTIVE: Our aim was to test the hypothesis that anticardiolipin antibodies (aCL) may cause an antiphospholipid syndrome and thrombotic events in patients with liver disease. METHODS: aCL were measured in 116 healthy controls and 372 patients with liver disease of different stage and etiology: 136 cases secondary to hepatitis C virus (HCV) infection, 139 due to hepatitis B virus (HBV) infection, 69 with alcoholic liver damage, and 28 cryptogenic in origin. Prior thrombotic events were recorded. The results were related to age, gender, stage, severity, and etiology of the liver disease, as well as to the occurrence of organ- and nonorgan-specific autoantibodies. RESULTS: aCL were positive in 4.4% of controls and in 18.8% of patients (p <0.0002). Patients with aCL were more frequently men with an advanced cirrhosis and simultaneous occurrence of anti-smooth-muscle antibodies (ASMA) in serum (p <0.0006); their liver damage was often secondary to HBV (37.3%) or alcohol abuse (18.5%). At conditional logistic regression analysis, only the presence of ASMA (odds ratio [OR] = 3.02, 95% confidence interval [CI] 1.7-5.5, p = 0.0003), HBV (OR = 3.4, 95% CI 1.6-7.2, p = 0.0013), or alcoholic liver disease (OR = 5.3, 95% CI 2.3-12.2, p = 0.0001) were independently associated with aCL. Thrombosis was encountered in 24 patients (6.4%). At conditional logistic regression analysis, thrombosis was significantly associated with advanced age (OR = 1.07, 95% CI 1.0-1.1, p = 0.0094), development of hepatocellular carcinoma (OR = 17.8, 95% CI 1.6- 196.0, p = 0.01), HBV etiology (OR = 6.3, 95% CI, 1.6-24.6, p = 0.0076), or cryptogenic liver disease (OR = 54.8, 95% CI 5-599.9, p = 0.001). Of the five patients with newly documented portal thrombosis during the follow-up, only one tested positive for aCL. CONCLUSIONS: In patients with nonautoimmune liver disease, aCL production is an epiphenomenon of the liver damage and is not associated with thrombotic complications. These data do not support the hypothesis that HCV is a cause of the antiphospholipid syndrome.

AB - OBJECTIVE: Our aim was to test the hypothesis that anticardiolipin antibodies (aCL) may cause an antiphospholipid syndrome and thrombotic events in patients with liver disease. METHODS: aCL were measured in 116 healthy controls and 372 patients with liver disease of different stage and etiology: 136 cases secondary to hepatitis C virus (HCV) infection, 139 due to hepatitis B virus (HBV) infection, 69 with alcoholic liver damage, and 28 cryptogenic in origin. Prior thrombotic events were recorded. The results were related to age, gender, stage, severity, and etiology of the liver disease, as well as to the occurrence of organ- and nonorgan-specific autoantibodies. RESULTS: aCL were positive in 4.4% of controls and in 18.8% of patients (p <0.0002). Patients with aCL were more frequently men with an advanced cirrhosis and simultaneous occurrence of anti-smooth-muscle antibodies (ASMA) in serum (p <0.0006); their liver damage was often secondary to HBV (37.3%) or alcohol abuse (18.5%). At conditional logistic regression analysis, only the presence of ASMA (odds ratio [OR] = 3.02, 95% confidence interval [CI] 1.7-5.5, p = 0.0003), HBV (OR = 3.4, 95% CI 1.6-7.2, p = 0.0013), or alcoholic liver disease (OR = 5.3, 95% CI 2.3-12.2, p = 0.0001) were independently associated with aCL. Thrombosis was encountered in 24 patients (6.4%). At conditional logistic regression analysis, thrombosis was significantly associated with advanced age (OR = 1.07, 95% CI 1.0-1.1, p = 0.0094), development of hepatocellular carcinoma (OR = 17.8, 95% CI 1.6- 196.0, p = 0.01), HBV etiology (OR = 6.3, 95% CI, 1.6-24.6, p = 0.0076), or cryptogenic liver disease (OR = 54.8, 95% CI 5-599.9, p = 0.001). Of the five patients with newly documented portal thrombosis during the follow-up, only one tested positive for aCL. CONCLUSIONS: In patients with nonautoimmune liver disease, aCL production is an epiphenomenon of the liver damage and is not associated with thrombotic complications. These data do not support the hypothesis that HCV is a cause of the antiphospholipid syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0032859078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032859078&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.1999.01447.x

DO - 10.1111/j.1572-0241.1999.01447.x

M3 - Article

C2 - 10520856

AN - SCOPUS:0032859078

VL - 94

SP - 2983

EP - 2987

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 10

ER -